News & Insights

pexels-nappy
by GCT Admin

GCT-007 Plus Tamoxifen Synergistic Effect Treating Endocrine Therapy-Resistant Breast Cancer

For Immediate Release Contact: info@globalcancertechnology.com San Diego, CA – July

by GCT Admin

Global Cancer Technology Appoints Dr. Sanjeev Thohan as Chief Development Officer

Global Cancer Technology is a preclinical-stage biopharmaceutical company focused on advancing novel therapeutics for oncology. The company is currently raising investment capital to support its planned Phase I clinical trial.

by GCT Admin

Global Cancer Technology Secures Full Ownership of Groundbreaking Cancer-Fighting Patents

Global Cancer Technology has acquired full patent ownership for two potentially life-saving cancer treatments from Neuropore Therapies.

pexels-nappy
by GCT Admin

GLOBAL CANCER TECHNOLOGY FILES TO EXPAND IP PORTFOLIO

pexels-nappy
by GCT Admin

Pre-Clinical results from the University of Colorado shows GCT-007 more effective than Paxalisib TM at lower concentrations

pexels-nappy
by GCT Admin

Pre-Clinical data from the University of Wisconsin confirms GCT-007 has low toxicity properties and crosses the Blood Brain Barrier

pexels-nappy
by GCT Admin

GLOBAL CANCER TECHNOLOGY SHOWS PROMISING PRE-CLINICAL DATA WITH GCT-007 AND CHECKPOINT INHIBITOR TREATING TAMOXIFEN-RESISTANT BREAST CANCER

pexels-nappy
by GCT Admin

Global Cancer Technology’s GCT-007 receives promising pre-clinical results from the University of Colorado Anschutz Medical School

pexels-nappy
by GCT Admin

GLOBAL CANCER TECHNOLOGY PATENTS ISSUED IN JAPAN

pexels-nappy
by GCT Admin

GLOBAL CANCER TECHNOLOGY’S PI3K inhibitor drug shows promising preclinical results for the treatment of Glioblastoma multiforme (GBM)

pexels-nappy
by GCT Admin

GCT-007 CONTINUES TO RECEIVE EXCEPTIONAL GLIOBLASTOMA PRE-CLINICAL RESULTS

pexels-nappy
by GCT Admin

Global Cancer Technology’s GCT-007 receives promising pre-clinical results from the Baylor College of Medicine

12/45